Context Therapeutics Inc. 8-K

What Happened
Context Therapeutics Inc. filed a Form 8-K (dated Feb 27, 2026) disclosing that a stipulation and proposed consent judgment was submitted to the Delaware Court of Chancery on Feb 24, 2026 in response to a Feb 4, 2026 stockholder class action by the Vladimir Gusinsky Revocable Trust. The Stipulated Judgment asks the Court to declare invalid and unenforceable two Charter provisions: (1) Article V, Section 2 (directors serve three-year terms) and (2) Article VI, Section 1 (directors removable only for cause). The parties seek dismissal of the action with prejudice. If the Court approves the Stipulated Judgment, the Company will file a Certificate of Correction with the Delaware Secretary of State to reflect those provisions as invalid and no longer part of the Charter.

Key Details

• Stipulated Judgment filed with Delaware Court of Chancery: Feb 24, 2026; 8-K filed: Feb 27, 2026.
• Company states the 2026 annual meeting of stockholders will be held on June 24, 2026; record date: April 27, 2026.
• If approved, Company will propose director elections to one-year terms (each director elected for a one-year term and until a successor is elected/qualified).
• Stockholder nomination deadlines: advance notice to Corporate Secretary by 5:00 p.m. EDT on March 14, 2026 (Bylaws requirement); Rule 14a-19 universal proxy notice by April 13, 2026 for competing director nominees.

Why It Matters
This filing addresses corporate governance provisions in Context’s Charter that set multi-year director terms and restricted removal to “for cause.” If the Court approves the Stipulated Judgment and the Charter is corrected, the Company will move to annual one-year director terms and related election procedures, and the scheduled June 24, 2026 annual meeting and nomination timelines become operative. Investors should note the voting schedule and nomination deadlines if they intend to propose actions or nominate directors. The 8-K also includes standard forward-looking statement disclaimers.